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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common 
neurodevelopmental disorder, with an estimated prevalence of 
5–7% in children and adolescents (Faraone et al., 2003; Froehlich 
et al., 2007; Polanczyk et al., 2007, 2015). ADHD often persists 
beyond childhood, with the prevalence in adults reported to be 
3–5%, with some variability across countries (Fayyad et al., 2007; 
Simon et al., 2009). Guidelines from the European Medicines 
Agency (EMA) recommend that clinical trials of ADHD medica-
tions report responder analyses, as well as evaluate symptomatic 
outcomes at the group level, in order to understand the benefits (or 
otherwise) of investigational treatments better at the level of the 
individual participants, thus providing health-care professionals 
with an indication of the likelihood of success with a particular 
treatment regimen (European Medicines Agency, 2010).
Clinical response may be based on improvements in symptom 
scales such as the ADHD Rating Scale IV (ADHD-RS-IV; 
DuPaul et al., 1998), the Swanson, Nolan and Pelham version IV 
(SNAP-IV; Bussing et al., 2008; Swanson et al., 2001) and the 
Conners’ Parent Rating Scale-Revised (Conners et al., 1998), 
with or without a Clinical Global Impressions – Improvement 
(CGI-I) score of 1 (very much improved) or 2 (much improved; 
Banaschewski et al., 2014; Busner and Targum, 2007; Coghill 
et al., 2013; Dittmann et al., 2013, 2014; Soutullo et al., 2013; 
Steele et al., 2006). However, there is currently no clear consen-
sus on appropriate thresholds for a clinically meaningful response 
using these instruments. Thresholds that have been used include 
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a CGI-I score of 1 or 2, either alone or in combination with a 
decrease in ADHD-RS-IV total score of at least 25% for a partial 
response or more than 50% for a more robust response (Biederman 
et al., 2007; Coghill et al., 2013, 2017; Dittmann et al., 2014, 
2013; Findling et al., 2010, 2011, 2013; Jain et al., 2011; 
Mattingly et al., 2013). Some investigators argue that symptom 
score in responders should be within the range for unaffected 
individuals. To this end, a 65% reduction in symptom scale score 
has been proposed (Buitelaar et al., 2009), as has an ADHD-
RS-IV total score at the end point of ⩽18 – a score considered by 
some to represent symptom remission on treatment (Coghill and 
Seth, 2015; Soutullo et al., 2013).
To inform the selection of response thresholds, we compared 
post hoc response rates from a series of late-phase clinical trials 
of different designs that evaluated lisdexamfetamine dimesylate 
(LDX), the long-acting prodrug of amphetamine, in children and 
adolescents with ADHD. Several of the studies included active 
controls, either as a head-to-head comparator or as a reference 
arm. The evaluation of response was based on three different 
response criteria: a decrease of at least 30% in combination with 
a CGI-I score of 1 or 2; at least a 50% reduction in ADHD-RS-IV 
total score in combination with a CGI-I score of 1 or 2; and an 
ADHD-RS-IV total score of ⩽18 at the end point.
Methods
Ethics
All studies were conducted in accordance with current applicable 
international and national regulations and ethical requirements. 
For all studies, each participant’s parent or legally authorised 
guardian provided informed consent, and each participant pro-
vided assent if applicable.
Study designs
These post hoc analyses were based on six studies: four ran-
domised controlled trials (RCTs) (SPD489-325, SPD489-317, 
SPD489-405 and SPD489-406) and two open-label (OL) studies 
of LDX (SPD489-326 and SPD489-404). Osmotic-release oral 
system methylphenidate (OROS-MPH) was used as a head-to-
head comparator in SPD489-405 and SPD489-406, and as a ref-
erence arm in SP489-325. Atomoxetine (ATX) was included as a 
head-to-head comparator in SPD489-317. The study designs are 
summarised in Table 1. Further details are provided in the online 
Supplemental Material, and the full methods have been published 
previously (Coghill et al., 2013, 2014, 2017; Dittmann et al., 
2013; Newcorn et al., 2017). These six studies were selected 
because these were recent studies that all included the same 
response measures that could be used for post hoc analyses.
Measure of response
Response was defined according to three criteria: a reduction 
from baseline to the end point of at least 30% in ADHD-RS-IV 
total score in combination with a CGI-I score of 1 (very much 
improved) or 2 (much improved); a reduction from baseline to 
the end point of at least 50% in ADHD-RS-IV total score in com-
bination with a CGI-I score of 1 or 2; and an ADHD-RS-IV total 
score of ⩽18 at the end point.
Statistical analysis
Analyses were based on the full analysis set for each study. This 
included all participants who were randomised and received at 
least one dose of any investigational drug. Missing data were 
handled using the last observation carried forward method. Data 
from baseline measures were never carried forward into the treat-
ment phase. Participants who had only a baseline assessment and 
did not have any valid post-baseline data were excluded from the 
analyses. Proportions of responders were calculated for each 
treatment, with 95% confidence intervals. No direct statistical 
comparisons of treatment response were made between investi-
gational drugs.
Results
Participant disposition and characteristics
In total, 1823 participants received at least one dose of an investi-
gational drug in the six studies and were included in the full analy-
sis set. The LDX group comprised 1181 participants (six studies), 
the OROS-MPH group comprised 507 participants (three studies) 
and the ATX group comprised 135 participants (one study). After 
excluding individuals with no valid post-baseline data, responder 
analyses based on at least a 30% and at least a 50% reduction from 
baseline to the end point in ADHD-RS-IV total score included 
1809 participants (LDX, n=1171; OROS-MPH, n=506; ATX, 
n=132); analyses of patients achieving an ADHD-RS-IV total 
score of ⩽18 at the end point included 1818 participants (LDX, 
n=1178; OROS-MPH, n=507; ATX, n=133). Baseline character-
istics are reported in Table 2. Mean ADHD-RS-IV total scores at 
baseline were 40.5–42.6 across all treatment groups in the four 
studies that involved children and adolescents, and 36.6 and 37.8 
in the two adolescent-only studies. LDX was generally well toler-
ated across studies, and all safety results have been published in 
detail previously (Coghill et al., 2013, 2014, 2017; Dittmann 
et al., 2013; Newcorn et al., 2017).
Responder analysis
In the RCTs, the proportion of participants receiving LDX who 
achieved a reduction in ADHD-RS-IV total score of at least 30% 
with a CGI-I score of 1 or 2 at the end point ranged from 69.6% 
to 82.6%; the proportion achieving the more stringent criterion of 
a reduction in ADHD-RS-IV total score of at least 50% with a 
CGI-I score of 1 or 2 at the end point ranged from 59.8% to 
74.8% (Table 3).
In the OL studies, the response rate for a reduction in ADHD-
RS-IV total score of at least 30% with a CGI-I score of 1 or 2 at 
the end point was at least 75%, and almost 70% achieved a reduc-
tion in ADHD-RS-IV total score of at least 50% with a CGI-I 
score of 1 or 2 at the end point (Table 3).
The proportions of participants receiving LDX who achieved 
an ADHD-RS-IV total score of ⩽18 at the end point ranged from 
56.7% to 79.9% in the RCTs, and were 67.7% and 66.9% in the 
OL studies (Table 3).
The proportion of participants receiving OROS-MPH who 
achieved a reduction in ADHD-RS-IV total score of at least 30% 
plus a CGI-I score of 1 or 2 ranged from 53.8% to 80.4%, and 
was 62.9% for ATX (Table 3). The more robust response thresh-
old of a reduction in ADHD-RS-IV total score of at least 50% and 
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a CGI-I score of 1 or 2 was achieved by 45.3–67.9% of partici-
pants receiving OROS-MPH and by 46.2% of those receiving 
ATX (Table 3). An ADHD-RS-IV total score of ⩽18 was 
achieved by 48.6–69.6% of participants receiving OROS-MPH 
and 41.4% of those receiving ATX (Table 3).
In the RCTs and OL studies, response rates for all criteria 
increased during dose optimisation and escalation, and remained 
stable for the remainder of the trials – for up to two years in 
SPD489-404 (Figure 1). In the RCTs, response rates (all criteria) 
for OROS-MPH and ATX also increased during dose optimisa-
tion and escalation, and remained stable for the remainder of the 
trials (Figure 2).
Discussion
To provide an estimate of the clinical impact of treatment on indi-
vidual patients, the EMA recommends that clinical trials evaluate 
the proportion of responders based on symptom improvement in 
combination with functional improvements (European Medicines 
Agency, 2010). Therefore, we evaluated treatment response 
across six clinical trials of LDX in children and adolescents with 
ADHD, using three different criteria. The observed response rates 
for LDX for the criterion of at least a 30% decrease in ADHD-
RS-IV total score plus a CGI-I score of 1 or 2 was higher than for 
the more stringent thresholds of at least a 50% decrease in ADHD-
RS-IV total score plus a CGI-I score of 1 or 2, or an ADHD-RS-IV 
total score of ⩽18 at the end point. Response rates for LDX were 
similar across RCTs and, based on OL studies, were stable for up 
to two years. Although less extensive, the available data suggest 
similar rank orders in responder rates for the comparators OROS-
MPH and ATX, with the highest proportion of responders 
observed for the least strict response criterion.
The proportions of participants in the RCTs achieving a 
reduction of at least 30% in ADHD-RS-IV total score in combi-
nation with a CGI-I score of 1 or 2 at the end point ranged from 
approximately 70% to 83% for participants receiving LDX. 
These response rates are similar to those previously reported 
using the same criterion (Findling et al., 2010; Jain et al., 2011; 
Mattingly et al., 2013) but are lower than those observed when 
response was defined as a CGI-I score of 1 or 2 only (Biederman 
et al., 2007; Findling et al., 2011, 2013). As would be expected, 
smaller proportions of participants achieved the more stringent 
Table 1. Overview of studies included in the responder analyses.
Study Age, 
years
Number of 
participantsa 
(completed 
study)
Dose range Dose type Study length Design Location Primary 
publication
Randomised controlled trials
SPD489-325
NCT00763971
6–17 317 (196) LDX, 30–70 mg/day
OROS-MPH, 18–54 mg/day
Optimised 4 weeks of dose 
optimisation
3 weeks of dose 
maintenance
R DB PC PG
OROS-MPH refer-
ence arm
Europe Coghill et al. 
(2013)
SPD489-317
NCT01106430
6–17 262 (200) LDX, 30–70 mg/day
ATX (⩾70 kg),  
40–100 mg/day
ATX (<70 kg),  
0.5–1.4 mg/kg/day
Optimised 4 weeks of dose 
optimisation
5 weeks of dose 
maintenance
R DB PG
Head-to-head LDX 
vs. ATX
Inadequate re-
sponse to MPH
North America 
and Europe
Dittmann 
et al. (2013)
SPD489-405
NCT01552915
13–17 452 (380) LDX, 30–70 mg/day
OROS-MPH, 18–72 mg/day
Optimised 5 weeks of dose 
optimisation
3 weeks of dose 
maintenance
R DB PC PG
Head-to-head LDX 
vs. OROS-MPH
USA Newcorn 
et al. (2017)
SPD489-406
NCT01552902
13–17 532 (464) LDX, 70 mg/day
OROS-MPH, 72 mg/day
Forced 4 weeks of dose 
escalation
2 weeks of fixed 
dose
R DB PC PG
Head-to-head LDX 
vs. OROS-MPH
North America 
and Europe
Newcorn 
et al. (2017)
Open-label trials
SPD489-326
NCT00784654
6–17 262 (157) LDX, 30–70 mg/day Optimised 4 weeks of dose 
optimisation
⩾26 weeks of 
dose maintenance
6 weeks of RWb
PC PG
6-month open-label 
phase
6 weeks of DB RW
Europe and 
USA
Coghill et al. 
(2014)
SPD489-404
NCT01328756
6–17 299 (191) LDX, 30–70 mg/day Flexible 4 weeks of dose 
optimisation
100 weeks of dose 
maintenance
Open-label single 
group LDX
Europe Coghill et al. 
(2017)
aNumber of participants included in the full analysis set.
bData from randomised withdrawal phase are not included in these analyses.
ATX: atomoxetine; DB: double-blind; LDX: lisdexamfetamine dimesylate; MPH: methylphenidate; OROS-MPH: osmotic-release oral system methylphenidate; PC: placebo-
controlled; PG: parallel-group; R: randomised; RW: randomised-withdrawal.
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response criterion of a reduction of at least 50% in ADHD-RS-IV 
total score plus a CGI-I score of 1 or 2, and similar proportions of 
participants achieved symptom scores within the range of unaf-
fected individuals (i.e. ADHD-RS-IV score of ⩽18).
LDX treatment in the RCTs and OL studies included in these 
post hoc analyses resulted in group mean reductions in ADHD-
RS-IV total score of about 25 points (range 24.3–26.6 points) 
from baseline scores of about 40 points (range 36.6–42.6 points; 
Coghill et al., 2013, 2014, 2017; Dittmann et al., 2013; Newcorn 
et al., 2017). This reduction equates to a decrease of about 63%, 
and would result in an average ADHD-RS-IV total score within 
the range of unaffected individuals (i.e. a score of ⩽18 points). 
Despite this substantial and highly statistically significant 
decrease in mean ADHD-RS-IV score, the present data indicate 
that a sizeable minority of participants (⩾17.4%) did not meet 
any of the defined response criteria. Thus, by enabling the evalu-
ation of the clinical impact of a treatment in individual patients, 
response rates provide distinct but complementary information 
about treatment efficacy in addition to mean changes in symptom 
scale scores.
An important consideration when using proportional reduc-
tions in symptom scales as a measure of treatment response is 
that the score at the end point depends on the score at baseline. It 
has been shown that patients with higher symptom severity at 
baseline tend to have a larger response to immediate-release 
MPH than patients with lower symptom severity at baseline 
(Victor et al., 2014). However, an individual with the maximum 
ADHD-RS-IV total score of 54 at baseline would still experience 
significant symptoms at the end point, despite a 50% reduction in 
score. Rather than a proportional reduction in symptom score, it 
has therefore been argued that achieving symptom scale scores 
within the range of unaffected individuals (ADHD is considered 
unlikely if the ADHD-RS-IV total score is ⩽18 for the combined 
subtype; Coghill and Seth, 2015) should be the target of treat-
ment (sometimes termed symptom remission on treatment; Steele 
et al., 2006). Achieving an ADHD-RS-IV total score of ⩽18 will 
be more difficult for individuals with a high baseline score 
because they will need to achieve a larger improvement than 
individuals with lower scores. Choosing a realistic target for 
treatment response may also inform the choice of response crite-
rion that will be used in a clinical setting. An ADHD-RS-IV total 
of ⩽18 may not always be achievable, in which case a percentage 
reduction in ADHD-RS-IV total score plus a CGI-I score of 1 or 
2 may be the more appropriate criterion.
In the RCTs included in the present analyses, the proportions 
of LDX-treated participants who achieved an ADHD-RS-IV total 
score of ⩽18 (57–80%) were similar to previously reported val-
ues (Findling et al., 2010; Mattingly et al., 2013), and were gen-
erally lower than the proportion achieving at least a 30% decrease 
in ADHD-RS-IV total score plus a CGI-I score of 1 or 2, but 
broadly similar to response rates based on at least a 50% reduc-
tion from baseline in ADHD-RS-IV total score plus a CGI-I score 
of 1 or 2.
The increase in response to LDX in RCTs occurred largely 
during dose optimisation/escalation, mirroring the time course of 
the mean change from baseline in ADHD-RS-IV total scores pre-
viously reported for these trials (Coghill et al., 2013, 2017; 
Dittmann et al., 2013; Newcorn et al., 2017). Similar maximum 
response levels to those observed in the RCTs were observed in 
the OL studies, and mean response rates remained stable for up to 
two years. Whereas the longitudinal analyses of response in the 
OL studies provide no information about whether the proportion 
of responders at each time point comprise the same individuals, a 
previous one-year OL study of LDX in children with ADHD 
found that 96% of participants who completed dose optimisation 
met the clinical response criteria (a decrease of at least 30% in 
Table 3. Proportions of responders for LDX and comparators at the end point.
Trial Proportions of responders, % (95% CI) LS mean 
changes in 
ADHD-RS-IV 
total score 
from baselinea
⩾30% reduction in ADHD-
RS-IV total score and a 
CGI-I score of 1 or 2
⩾50% reduction in ADHD-
RS-IV total score and a 
CGI-I score of 1 or 2
Total ADHD-RS-
IV score ⩽18
LDX – randomised controlled trials
SPD489-325 69.6 (60.7–78.5) 59.8 (50.3–69.3) 56.7 (47.2–66.3) −24.3
SPD489-317 81.0 (74.1–87.8) 72.2 (64.4–80.0) 63.5 (55.1–71.9) −26.1
SPD489-405 82.6 (77.0–88.2) 74.2 (67.7–80.6) 79.9 (74.0–85.8) −25.6
SPD489-406 81.4 (76.2–86.7) 74.8 (68.9–80.6) 78.6 (73.0–84.1) −25.4
LDX – open-label studies
SPD489-326 75.8 (70.5–81.0) 68.0 (62.3–73.7) 67.7 (62.0–73.4) −26.6
SPD489-404 77.3 (72.5–82.0) 69.2 (64.0–74.5) 66.9 (61.6–72.2) −25.8
OROS-MPH
SPD489-325 53.8 (44.3–63.3) 45.3 (35.8–54.8) 48.6 (39.1–58.1) −18.7
SPD489-405 80.4 (74.7–86.2) 67.9 (61.2–74.7) 69.6 (62.9–76.2) −23.5
SPD489-406 70.4 (64.3–76.5) 62.0 (55.6–68.5) 63.0 (56.5–69.4) −22.1
ATX
SPD489-317 62.9 (54.6–71.1) 46.2 (37.7–54.7) 41.4 (33.0–49.7) −19.7
The end point was defined as the last study visit. Missing data were handled using the last observation carried forward method. Participants with missing or invalid post-
baseline data were excluded from the analyses.
aMean changes in ADHD-RS-IV total scores are available from the primary publications of the included studies (Coghill et al., 2013, 2014, 2017, Dittmann et al., 2013; 
Newcorn et al., 2017).
CGI-I: Clinical Global Impressions – Improvement; LS: least-squares.
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ADHD-RS-IV total score plus a CGI-I score of 1 or 2) at one or 
more visits, and about 63% met the criteria at each subsequent 
visit (response maintenance; Findling et al., 2010). Similarly, in a 
one-year OL study of LDX in adults with ADHD, more than 95% 
of participants met the response criteria at least once, with 75% 
meeting the criteria at all subsequent visits (Mattingly et al., 
2013). It should be noted that treatment response is reliant on 
continuous treatment, and a randomised withdrawal trial of LDX 
has shown that symptoms return after treatment cessation 
(Coghill et al., 2014).
We did not attempt to compare responses between LDX and 
either OROS-MPH or ATX, which were included in the RCTs here 
as either a head-to-head comparator or a reference treatment. For 
completeness, results are reported for these head-to-head compara-
tors and reference treatments when they were included in studies. 
It should be noted that each trial was designed and optimised to 
investigate the efficacy and safety of LDX rather than the com-
parators. Nevertheless, the rank orders of response to OROS-MPH 
and ATX based on each of the response criteria were similar to 
those observed with LDX, with the highest proportion of respond-
ers found for a reduction in ADHD-RS-IV total score of at least 
30% in combination with a CGI-I score of 1 or 2. Published 
response rates for OROS-MPH based on this criterion (62% and 
66%) are within the range of response rates found in the present 
analyses (Biederman et al., 2006, 2010). Likewise, published val-
ues for the proportions of OROS-MPH-treated participants who 
achieved symptom remission based on SNAP-IV scores (69.3% 
and 73.2%) are similar to the proportions of participants in the pre-
sent analyses who achieved an ADHD-RS-IV total score of ⩽18 at 
the end point (Su et al., 2015). With regard to ATX treatment, the 
proportion of participants achieving at least a 30% reduction in 
ADHD-RS-IV total score plus a CGI-I score of 1 or 2 in the present 
analyses was similar to the 60% who achieved a 25% reduction in 
ADHD-RS-IV total score in a large retrospective study (1069 
patients) that investigated predictive factors for response to ATX 
(Newcorn et al., 2009).
The strengths of these post hoc analyses are the large number of 
participants for whom data were analysed and the relatively 
Figure 1. Time course of response rates to LDX across all studies. ADHD-RS-IV: Attention-Deficit/Hyperactivity Disorder Rating Scale IV; CGI-I: 
Clinical Global Impressions – Improvement; LDX: lisdexamfetamine dimesylate; LOTA: last on-treatment assessment. Data are based on the full 
analysis set using last observation carried forward. Participants without any valid post-baseline data were excluded from these analyses. The 
proportion of responders at each visit is shown for the randomised controlled trials in (a) SPD489-325, (b) SPD489-317, (d) SPD489-405 and (e) 
SPD489-406, and for the open-label studies in (c) SPD489-326 and (f) SPD489-404.
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consistent results across several clinical trials. However, several 
factors should be considered when interpreting these data. First, 
the inclusion criteria and design differed between trials, and so data 
could not be pooled. Specifically, the differences in maximum 
doses of OROS-MPH across studies (maximum of 54 mg/day in 
Europe and 72 mg/day in the USA and Canada) are an important 
limitation because it has been established that many patients need 
more than 54 mg/day. Second, the OROS-MPH and ATX data sets 
were smaller than that for LDX, and the included trials were 
designed and powered to investigate LDX rather than comparator 
medications. So, direct comparisons of responder rates for the dif-
ferent treatments were not possible. It should also be noted that not 
all participants completed the trials they were in. There are caveats 
with using a last observation carried forward method, and mainte-
nance of treatment response should be considered carefully in light 
of this methodology. Finally, with response based on ADHD-
RS-IV and CGI-I scores, the present data largely focus on sympto-
matic improvement rather than on treatment efficacy (Adamo 
et al., 2015). The importance of including non-symptomatic out-
come measures in clinical trials of ADHD medications is 
increasingly recognised (Wong et al., 2019). Unfortunately, such 
measures are not yet consistently applied to clinical trials of ADHD 
medications, and appropriate functional and health-related quality-
of-life response thresholds have yet to be agreed.
In summary, the present post hoc analyses compared three dif-
ferent commonly used definitions of treatment response in six 
clinical trials of LDX in children and adolescents with ADHD. 
The results indicate that treatment with LDX and the comparator 
medications, OROS-MPH and ATX, all resulted in high response 
rates that are consistent across different study designs and popu-
lations. Further, there is no evidence to suggest that specific 
response criteria favour the different treatments. Response rates 
were higher for a ⩾30% reduction from baseline in ADHD-
RS-IV total score plus a CGI-I score of 1 or 2 than for a ⩾50% 
reduction in ADHD-RS-IV total score plus a CGI-I score of 1 or 
2 and an ADHD-RS-IV total score of ⩽18, suggesting that the 
first criterion is a measure of partial response in these six clinical 
trials, at least in some individuals. Based on these findings, it 
should be possible to reach a significant improvement in approxi-
mately 60% (ATX) to 80% (LDX and OROS-MPH) of patients 
Figure 2. Time course of response rates to ATX and OROS-MPH across the four randomised controlled trials. ADHD-RS-IV: Attention-Deficit/
Hyperactivity Disorder Rating Scale IV; ATX: atomoxetine; OROS-MPH: osmotic-release oral system methylphenidate. Data shown are based on the 
full analysis set using last observation carried forward. Participants without any valid post-baseline data were excluded from these analyses. The 
proportion of responders to OROS-MPH at each visit is shown for (a) SPD489-325, (c) SPD489-405 and (d) SPD489-406. The proportion of responders 
to ATX at each visit is shown for (b) SPD489-317.
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and – more importantly – to achieve substantial improvement or 
symptom scores within the range of unaffected individuals in 
around 2/5 (ATX) and 2/3 (LDX and OROS-MPH) patients. 
Therefore, the stricter response criteria may be more appropriate 
in a clinical setting when aiming to find the optimal response for 
patients compared to the less strict criterion, even if this may be 
difficult to achieve in routine clinical practice. Symptom severity 
at baseline should of course be considered when assessing 
improvement in relation to symptom reduction scores. For exam-
ple, an individual with a particularly high baseline score will find 
it challenging to achieve the lowest possible absolute score. 
Consistent use of response rate criteria is required to understand 
treatment response better at the level of the individual.
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